The short version of SR9009 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-01-29. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
PDBsum has links to three-dimensional structures of various alcohol dehydrogenases contained in the Protein Data Bank ExPASy contains links to the alcohol dehydrogenase sequences in Swiss-Prot, to a Medline literature search about the enzyme, and to entries in other databases. PDBe-KB provides an overview of all the structure information available in the PDB for Alcohol dehydrogenase 1A. PDBe-KB provides an overview of all the structure information available in the PDB for Alcohol dehydrogenase 1B. PDBe-KB provides an overview of all the structure information available in the PDB for Alcohol dehydrogenase 1C. PDBe-KB provides an overview of all the structure information available in the PDB for Alcohol dehydrogenase 4. PDBe-KB provides an overview of all the structure information available in the PDB for Alcohol dehydrogenase class-3.
=== Languages === The official language of Schleswig-Holstein is German. In addition, Low German, Danish and North Frisian are recognized minority languages. Historically, Low German (in Holstein and Southern Schleswig), Danish (in Schleswig), and North Frisian (in Western Schleswig) were widely spoken in Schleswig-Holstein. During the language change in the 19th century some Danish and North Frisian dialects in Southern Schleswig were replaced by Standard German. Low German is still used in many parts of the state. Missingsch, a Low German dialect with heavy High German (Standard German) influence, is commonly spoken informally throughout the state, while a mixed language Petuh (mixture of High German and Danish) is used in and around Flensburg. Danish is used by the Danish minority in Southern Schleswig, and North Frisian is spoken by the North Frisians of the North Sea Coast and the Northern Frisian Islands in Southern Schleswig. The North Frisian dialect called Heligolandic (Halunder) is spoken on the island of Heligoland. As is the case throughout Germany, High German, introduced in the 16th century, has come to steadily replace local dialects for official purposes, and is today the predominant language of media, law, and legislature. It is spoken by virtually all inhabitants in formal situations. Since the end of World War II and the widespread adoption of TV, radio, and other mass media, it has gradually come to supplant local dialects in urban areas as well.
Over the next three years, 1st SFG (A) members built an significant record in the Philippines training six light infantry battalions, three light reaction companies from the Armed Forces of the Philippines (AFP), treating over 31,000 Filipinos in MEDCAP events, helping to professionalize the AFP, and providing operations and intelligence fusion teams to actively assist the AFP in targeting militant cells. Throughout 2003–2004, the 1st SFG (A) deployed numerous personnel in support of Operation Iraqi Freedom and Operation Enduring Freedom in Iraq and Afghanistan respectively. By November 2004 the unit deployed an entire battalion to Afghanistan as part of the Combined Joint Special Operations Task Force- Afghanistan (CJSOTF-A). Today, 1st SFG (A) supported the global war on terrorism with operations in the Philippines, Iraq and Afghanistan as well as maintaining US security relationships with partner nations throughout the Pacific until 2021.
Co-founder of Petra Pharma (with Nathanael Gray). Co-founder of Agios Pharmaceuticals (with Tak Mak and Craig B. Thompson). Co-founder of Volastra Therapeutics (with Sam Bakhoum and Olivier Elemento), developing treatments targeting chromosomal instability in cancer. Co-founder of Marendis Therapeutics (with Tomer Yaron-Barir and Olivier Elemento), targeting drug resistance in cancer.
Sources: en.wikipedia.org
The revived Mannerist sphinx of the late 15th century is sometimes thought of as the "French sphinx". Her coiffed head is erect and she has the breasts of a young woman. Often she wears ear drops and pearls as ornaments. Her body is naturalistically rendered as a recumbent lioness. Such sphinxes were revived when the grottesche or "grotesque" decorations of the unearthed Domus Aurea of Nero were brought to light in late 15th-century Rome, and she was incorporated into the classical vocabulary of arabesque designs that spread throughout Europe in engravings during the 16th and 17th centuries. Sphinxes were included in the decoration of the loggia of the Vatican Palace by the workshop of Raphael (1515–20), which updated the vocabulary of the Roman grottesche. The first appearances of sphinxes in French art are in the School of Fontainebleau in the 1520s and 1530s and she continues into the Late Baroque style of the French Régence (1715–1723). From France, she spread throughout Europe, becoming a regular feature of the outdoors decorative sculpture of 18th-century palace gardens, as in the Upper Belvedere Palace in Vienna, Sanssouci Park in Potsdam, La Granja in Spain, Branicki Palace in Białystok, or the late Rococo examples in the grounds of the Portuguese Queluz National Palace (of perhaps the 1760s), with ruffs and clothed chests ending with a little cape.
Deslorelin, sold under the brand name Suprelorin among others, is an injectable gonadotropin releasing hormone superagonist (GnRH agonist) which is used in veterinary medicine for various indications.
Tarui disease (GSD-VII) patients do not experience the "second wind" phenomenon; instead are said to be "out-of-wind." However, they can achieve sub-maximal benefit from lipid metabolism of free fatty acids during aerobic activity following a warm-up.
Sources: en.wikipedia.org
Insulin tregopil, in development by Biocon Insulin efsitora alfa, made by Lilly ORMD-0801, an oral analogue produced by Oramed NNC2215, a glucose-sensitive insulin being researched by Novo Nordisk OI338 and OI320, two basal oral analogues also by Novo Nordisk LAPS Insulin115, an ultralong analogue being researched by Hanmi Pharm
=== 2009 === A report prepared for the British House of Lords comes to the conclusion that "The precise circumstances surrounding the August 2008 outbreak of the conflict are not yet clear but responsibility for the conflict was shared, in differing measures, by all the parties. There is evidence of a Russian military build-up prior to the August war." On 17 February 2009, the commanding General of the United States Army Europe Carter Ham commented on the training of Georgian military that the United States had trained the Georgian military for Iraq in the previous years, not for the defense of the homeland against Russia. In May 2009, anonymous European diplomat told The New York Times that NATO officials were told in April 2008 by Russia's defense chief that Georgia would be invaded later that year. In July 2009, Alexander Bastrykin, Chairman of the Investigative Committee of the Prosecutor General's Office, told journalists that the investigation of the war was almost complete. However, the guilt of Georgian president Mikheil Saakashvili in instigating the conflict in South Ossetia could not be proven. In September 2009, first president of the Czech Republic Václav Havel, Otto von Habsburg and other European politicians and thinkers wrote: "First, a big power will always find or engineer a pretext to invade a neighbour whose independence it resents. We should remember that Hitler accused the Poles of commencing hostilities in 1939, just as Stalin pinned the blame on the Finns when he invaded their country in 1940.
=== Emergency medicine === He accepted a position as director of an emergency room at the University of Virginia, where he made several advances in emergency care: an emergency medical communication system for ambulances, emergency training for ambulance attendants, a rape crisis center, a crisis center for the deaf, a poison control center, an advanced life support emergency medical system, and the first medical air transport system in the Commonwealth of Virginia. Edlich was one of eight physician technical advisors for the Department of Emergency Medical Services of the US Department of Health Education and Welfare to develop emergency medical systems throughout the US. He supervised the development of emergency medical systems in the Virginia, Pennsylvania, West Virginia, Maryland, Washington DC, and Puerto Rico. In 1979, Edlich received the Distinguished Public Service Award for Contributions to Emergency Medicine by the US Public Health Service.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.